We used crude AD patient–derived brain homogenates as the seed in a tau biosensor cell assay, which revealed a dose-dependent inhibition of seeding by both OFA and OFB treatment groups, as compared to mock-treated controls (Fig 4F–J). Here, MAPT is linked to Alzheimer disease.